Enjoy complimentary customisation on priority with our Enterprise License!
The dravet syndrome treatment market is estimated to grow by USD 575.14 million at a CAGR of 9.6% between 2022 and 2027. The growth of the market depends on several factors, including growth in special regulatory designations, increasing new product launches, and advancements in genetic therapeutics for DS treatment.
To learn more about this report, Download Report Sample
The growth in special regulatory designations is notably driving the market growth, although factors such as low awareness may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growth in special regulatory designations is notably driving the market growth. The US Food and Drug Administration (FDA) has developed distinct and successful approaches to the rapid approval of drugs for serious diseases. Regulatory agencies such as the US FDA and EMA grant orphan drug designations, fast-track drug designations, and breakthrough drug designations to speed up the drug development and approval process.
In addition, the US FDA granted orphan drug designation in November 2021 to Neuroene Therapeutics' NT102, which can treat seizure symptoms in Dravet syndrome. In addition, in August 2021, EPIDYOLEX, manufactured by GW Pharmaceuticals, received orphan drug designation from the EMA for the treatment of LGS and DS attacks. These regulatory policies encourage pharmaceutical companies to develop drugs for rare diseases such as DS, which in turn boosts the growth of the global DS treatment market during the forecast period.
Increased use of new-generation drugs is one of the major market trends. FGDs such as clobazam and valproate have been used in the treatment of DS for decades. However, they are associated with side effects and have a limited therapeutic effect and complex pharmacokinetics.
In the 1990s and early 2000s, SGDs such as stiripentol and topiramate and other antiepileptic drugs such as lamotrigine, levetiracetam, and gabapentin entered the market. Later, as research and development increased, TGDs such as clonazepam, zonisamide, and ethosuximide came on the market. Compared to FGD, new-generation drugs have fewer side effects and wide therapeutic areas. Therefore, the use of new-generation drugs is higher than that of previous generations. However, SGD drugs are used more than TGD because they are more effective in treating DS. Therefore, the introduction of new-generation drugs will contribute to the growth of global DS treatment during the forecast period.
Low awareness is the major challenge impeding market growth. DS is a rare and severe type of epilepsy in babies. Children usually have psychomotor development before the onset of seizures. In most cases, the first attacks are accompanied by fever, which causes convulsions. In most cases, parents do not understand the symptoms of the disease, and even doctors are not able to recognize the disease as DS. In DS, relapse occurs after the first attacks. Parents are not aware of seizures, and this leads to misunderstandings about the symptoms of the disease. If parents are aware and adequately informed through medical professionals or awareness programs, the second episode of seizures is less painful for children.
Parents should be aware of the high risk of seizures, the treatment options, and the disease. Doctors are less aware of alternative treatments for the disease and usually treat the patient with anti-epileptic drugs. But they are not enough for treatment out of 100. Thus, a lack of awareness among parents and doctors poses a challenge to the growth of the global DS treatment market during the forecast period.
The market growth analysis report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
UCB SA - The company offers Dravet syndrome treatment in the form of an oral solution called FINTEPLA for patients 2 years of age and older.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about 15 market Companies, including:
Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.
The market share growth of the SGDs segment will be significant during the forecast period. SGDs are the largest segment of the global DS treatment market in 2022 and will continue to remain the largest segment during the forecast period. SGDs are widely used for the treatment of DS, as they are advantageous over FGDs regarding pharmacokinetics, safety, and tolerability. Currently, stiripentol and topiramate are the only available SGDs for the treatment of DS.
Get a glance at the market contribution of various segments Request a PDF Sample
The second-generation drug (SGDs) segment was valued at USD 274.97 million in 2017 and continued to grow until 2021. Another anti-epileptic agent that acts through multiple mechanisms is Topiramate. It helps in the blockage of voltage-gated-dependent sodium channels, carbonic anhydrase enzyme inhibition, aminomethylphosphonic acid (AMPA)/kainite receptor antagonism, and by enhancing the activity of gamma-aminobutyric acid (GABA) at GABA receptors. Thus, the increasing prevalence of DS, especially among children, will increase the demand for stiripentol and topiramate, which will boost the development of the SGDs segment of the global DS treatment market during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
North America is the largest geographical segment of the global DS treatment market in 2022 and will continue to remain the largest segment during the forecast period. This is primarily due to increasing initiatives and funding by various organizations to support the development of new treatments for DS.
The US and Canada are the major revenue contributors to the DS treatment market in North America. The market in these countries is driven by the presence of established medical facilities and the increasing healthcare spending by individuals.
The Dravet Syndrome Treatment Market, primarily in the United States, has witnessed significant advancements since June 2018, with regulatory approvals for medications like Stiripentol (Diacomit) and Epidiolex, a cannabidiol-based drug derived from marijuana. These breakthroughs, along with the emergence of Zogenix's ZX008 (Fintepla), have revolutionized treatment options for Dravet Syndrome patients. Medical equipment, research centers, and physicians play vital roles in diagnosing and managing the condition, characterized by myoclonic, partial, and absence seizures. Hospitals, diagnostic laboratories, and academic institutes collaborate to provide comprehensive care to epilepsy patients, utilizing antiepileptic medications and innovative therapies. The Dravet Foundation supports research initiatives and fosters collaboration among end-users, including healthcare professionals and patients, to improve outcomes and quality of life for individuals affected by this rare neurological disorder.
The market forecasting report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Dravet Syndrome Treatment Market Scope |
|
Market Report Coverage |
Details |
Page number |
163 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.6% |
Market growth 2023-2027 |
USD 575.14 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
9.0 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., BIOCODEX SAS, Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc., UCB SA, Viatris Inc., and Xenon Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.